Author pages are created from data sourced from our academic publisher partnerships and public sources.
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
- D. Zimbroff, J. Kane, +6 authors K. B. Kashkin
- Psychology, Medicine
- The American journal of psychiatry
- 1 June 1997
OBJECTIVE This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the… Expand
Hooked on hormones? An anabolic steroid addiction hypothesis.
Widespread illicit anabolic steroid use has recently been reported. A review of available evidence suggests that elevations of serum levels of steroid hormones, including anabolic steroids, have… Expand
Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety
- C. Tamminga, R. Mack, G. R. Granneman, C. Silber, K. B. Kashkin
- Psychology, Medicine
- International clinical psychopharmacology
- 1 February 1997
Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12–24 mg/day. Its action against positive symptoms is as potent as that of the traditional… Expand
P.3.024: The efficacy and safety of three doses of sertindole versus three doses of haloperidol in schizophrenic patients
Hooked on Hormones-Reply
In Reply. — We thank Drs Rosse and Deutsch for presenting their evidence for the interaction of sex steroids with benzodiazepine/γ-aminobutyric acidA receptors. There is other evidence for such… Expand
A pilot study of the efficacy and safety of A-81418 in reducing symptoms of nicotine withdrawal
Formulations pharmaceutiques d'activateurs de canaux potassiques ATP et leurs utilisations
Pharmaceutical formulations potassium channel activators ATP and uses thereof
A pharmaceutical controlled release formulation comprising a KATP channel activator of Formula ** ** wherein in Formulas II and III: R1 is selected from the group consisting of hydrogen, lower alkyl,… Expand
Pharmaceutical formulations openers dependent potassium channels of atp and uses thereof.
A pharmaceutical sustained release formulation of a KATP opening agent channels ** (See formula) ** In the Formulas II and III: R1 is selected from the group consisting of hydrogen, lower alkyl,… Expand
Salts openers potassium channel ATP-dependent and uses thereof.
Use of a formulation according to claim 8 for the manufacture of a pharmaceutical for (i) inhibiting secretion of fasting insulin, inhibit insulin secretion stimulated by glucose, elevating energy… Expand